SCM Lifescience Co., Ltd. (KOSDAQ:298060)
South Korea
· Delayed Price · Currency is KRW 849.00
-47.00 (-5.25%)
At close: Jun 13, 2025, 3:30 PM KST
SCM Lifescience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,171 | 824.8 | 695.7 | 395.98 | 439.26 | 320.01 | Upgrade
|
| Other Revenue | - | - | - | - | -0 | - | Upgrade
|
| Revenue | 1,171 | 824.8 | 695.7 | 395.98 | 439.26 | 320.01 | Upgrade
|
| Revenue Growth (YoY) | 41.80% | 18.56% | 75.69% | -9.85% | 37.27% | 89.92% | Upgrade
|
| Cost of Revenue | 762.03 | 511.75 | 379.54 | 245.84 | 134.82 | 94.2 | Upgrade
|
| Gross Profit | 408.83 | 313.05 | 316.16 | 150.14 | 304.44 | 225.8 | Upgrade
|
| Selling, General & Admin | 3,143 | 3,906 | 3,875 | 3,209 | 1,493 | 7,089 | Upgrade
|
| Research & Development | 6,710 | 7,596 | 9,315 | 9,311 | 10,473 | 8,846 | Upgrade
|
| Other Operating Expenses | 33.75 | 32.67 | 32.18 | 43.73 | 92.69 | 26.77 | Upgrade
|
| Operating Expenses | 9,965 | 11,621 | 13,314 | 12,729 | 12,460 | 16,315 | Upgrade
|
| Operating Income | -9,556 | -11,308 | -12,998 | -12,579 | -12,155 | -16,089 | Upgrade
|
| Interest Expense | -289.09 | -259.95 | -312.57 | -238.79 | -197.63 | -507.54 | Upgrade
|
| Interest & Investment Income | 134.31 | 238.72 | 86.83 | 246.86 | 202.12 | 178.69 | Upgrade
|
| Earnings From Equity Investments | - | - | -10,673 | -11,650 | -9,999 | 9,186 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.98 | 0.7 | 0.71 | 2.07 | -2.66 | -69.65 | Upgrade
|
| Other Non Operating Income (Expenses) | -232.11 | -291.47 | -6.54 | -11.44 | -3.99 | -2,113 | Upgrade
|
| EBT Excluding Unusual Items | -9,941 | -11,620 | -23,902 | -24,230 | -22,156 | -9,415 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,092 | -1,086 | -59.16 | 1,300 | -362.15 | -216.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | -267.05 | -267.05 | - | - | -0.48 | -1.38 | Upgrade
|
| Asset Writedown | -65.27 | -65.27 | - | - | - | - | Upgrade
|
| Pretax Income | -11,365 | -13,038 | -23,961 | -22,930 | -22,519 | -9,633 | Upgrade
|
| Income Tax Expense | -661.37 | -661.37 | - | - | - | - | Upgrade
|
| Net Income | -10,704 | -12,377 | -23,961 | -22,930 | -22,519 | -9,633 | Upgrade
|
| Net Income to Common | -10,704 | -12,377 | -23,961 | -22,930 | -22,519 | -9,633 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 20 | 16 | 15 | 12 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 20 | 16 | 15 | 12 | 11 | Upgrade
|
| Shares Change (YoY) | 20.45% | 25.01% | 12.85% | 21.21% | 12.79% | 101.51% | Upgrade
|
| EPS (Basic) | -481.73 | -604.92 | -1464.00 | -1581.00 | -1882.00 | -908.00 | Upgrade
|
| EPS (Diluted) | -481.73 | -604.92 | -1464.00 | -1581.00 | -1882.00 | -908.00 | Upgrade
|
| Free Cash Flow | -17,438 | -14,127 | -12,372 | -11,689 | -14,080 | -12,370 | Upgrade
|
| Free Cash Flow Per Share | -784.82 | -690.44 | -755.88 | -805.93 | -1176.70 | -1165.98 | Upgrade
|
| Gross Margin | 34.92% | 37.95% | 45.45% | 37.92% | 69.31% | 70.56% | Upgrade
|
| Operating Margin | -816.14% | -1370.97% | -1868.29% | -3176.64% | -2767.18% | -5027.71% | Upgrade
|
| Profit Margin | -914.17% | -1500.61% | -3444.23% | -5790.66% | -5126.47% | -3010.19% | Upgrade
|
| Free Cash Flow Margin | -1489.36% | -1712.75% | -1778.30% | -2951.85% | -3205.28% | -3865.43% | Upgrade
|
| EBITDA | -8,691 | -10,449 | -12,158 | -11,538 | -11,020 | -14,858 | Upgrade
|
| D&A For EBITDA | 864.99 | 859.21 | 839.44 | 1,041 | 1,136 | 1,231 | Upgrade
|
| EBIT | -9,556 | -11,308 | -12,998 | -12,579 | -12,155 | -16,089 | Upgrade
|
| Advertising Expenses | - | 208.18 | 278.13 | 146.98 | 217.7 | 148.49 | Upgrade
|
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.